What advantage does the re-TUR offer in non-muscle invasive bladder cancer, when is it really necessary and can PDD help us with these questions?

E. Sailer; Stefan Krause; Sebastian Graf; V. Tauber

doi:10.1016/S1569-9056(19)30567-6

What advantage does the re-TUR offer in non-muscle invasive bladder cancer, when is it really necessary and can PDD help us with these questions?

E. Sailer
, Stefan Krause
, Sebastian Graf
, V. Tauber

Department of Urology and Andrology

Research output: Contribution to journal › Article › peer-review

Abstract

Abstracts EAU19 – 34th Annual EAU Congress
15 March 2019 - 19 March 2019

Original language	English
Pages (from-to)	e774-e775
Journal	European Urology Supplements
Volume	18
Issue number	1
DOIs	https://doi.org/10.1016/S1569-9056(19)30567-6
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Fields of science

302005 Andrology
302086 Urology

Access to Document

10.1016/S1569-9056(19)30567-6

https://linkinghub.elsevier.com/retrieve/pii/S1569905619305676

Cite this

@article{6863c8c9ac554a299c30679f2938d6f6,

title = "What advantage does the re-TUR offer in non-muscle invasive bladder cancer, when is it really necessary and can PDD help us with these questions?",

abstract = "Abstracts EAU19 – 34th Annual EAU Congress 15 March 2019 - 19 March 2019",

author = "E. Sailer and Stefan Krause and Sebastian Graf and V. Tauber",

year = "2019",

doi = "10.1016/S1569-9056(19)30567-6",

language = "English",

volume = "18",

pages = "e774--e775",

journal = "European Urology Supplements",